Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 3 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
2 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, Yesterday

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.

Trametinib improves PFS in low-grade serous ovarian or peritoneal cancer

Elaine Soliven
12 May 2020

Treatment with trametinib, an MEK inhibitor, significantly improves progression-free survival (PFS) in patients with recurrent low-grade serous ovarian or peritoneal carcinoma (LGSOC) compared with standard of care (SOC), according to a study presented at SGO 20/20.

This phase II/III trial evaluated 260 patients diagnosed with recurrent or progressive LGSOC who had >3 lines of prior therapy between February 2014 and April 2018. Participants were randomized in a 1:1 ratio to receive either trametinib 2 mg/day or physician’s choice of SOC agent, ie, weekly paclitaxel, pegylated liposomal doxorubicin, topotecan, letrozole, or tamoxifen. Patients who experienced disease progression with SOC were crossed over to receive trametinib. [SGO 20/20, abstract 42]

At a median follow-up of 31.4 months, PFS was significantly improved in the trametinib arm compared with the SOC arm (median 13.0 vs 7.2 months; hazard ratio [HR], 0.48, 95 percent confidence interval [CI], 0.36–0.64; p<0.0001).

Exploratory analysis of the 88 patients who were crossed over to trametinib therapy showed a median PFS of 10.8 months (95 percent CI, 7.3–12.0) and median objective response rate (ORR) of 15 percent (95 percent CI, 0.07–0.22) in this group.

Patients treated with trametinib also achieved a longer duration of response (median 13.63 vs 5.88 months) and overall survival (median OS 37.0 vs 29.2 months; HR, 0.75, 95 percent CI, 0.51–1.11) than those who received SOC.

There was no significant difference between treatment arms for patient-reported quality of life outcomes.

The most common grade 3 adverse events reported in the trametinib arm vs the SOC arm were gastrointestinal (27.6 percent vs 29 percent), vascular (18.9 percent vs 8.6 percent), skin (15.0 percent vs 3.9 percent), and haematologic (13.4 percent vs 9.4 percent) toxicities.

LGSOC is a rare subtype, accounting for 5–10 percent of all serous cancers and is characterized by alterations in the MAPK pathway, relative chemoresistance, and prolonged OS compared to high-grade serous carcinoma,” said study lead author Dr David Gershenson from the University of Texas MD Anderson Cancer Center in Houston, Texas, US, and co-authors.

Overall, patients with recurrent LGSOC who received trametinib therapy had significantly improved PFS and ORR, they concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
Pearl Toh, 3 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
2 days ago
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Christina Lau, Yesterday

Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.